Principal Financial Group Inc. Purchases New Holdings in Indivior PLC $INDV

Principal Financial Group Inc. acquired a new position in shares of Indivior PLC (NASDAQ:INDV) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 70,357 shares of the company’s stock, valued at approximately $1,696,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in INDV. CWM LLC bought a new stake in shares of Indivior during the 3rd quarter valued at $25,000. Raymond James Financial Inc. acquired a new position in Indivior in the second quarter valued at about $26,000. Amalgamated Bank bought a new stake in Indivior during the second quarter worth about $61,000. Blue Trust Inc. acquired a new stake in Indivior during the third quarter worth about $99,000. Finally, California State Teachers Retirement System bought a new position in Indivior in the 2nd quarter valued at about $112,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on INDV shares. HC Wainwright increased their price target on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Morgan Stanley restated an “overweight” rating and set a $36.00 target price on shares of Indivior in a research note on Wednesday, December 3rd. Zacks Research lowered Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Northland Securities set a $50.00 price target on Indivior in a report on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a research note on Wednesday, January 28th. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $39.33.

Indivior Stock Up 0.5%

Shares of INDV opened at $34.75 on Wednesday. The stock has a market cap of $4.34 billion, a PE ratio of 37.77 and a beta of 0.80. Indivior PLC has a 12-month low of $7.62 and a 12-month high of $38.00. The business has a 50-day simple moving average of $34.86 and a two-hundred day simple moving average of $29.45.

Insiders Place Their Bets

In other Indivior news, Director Daniel A. Ninivaggi purchased 775 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director owned 16,923 shares in the company, valued at $598,904.97. The trade was a 4.80% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Keith Humphreys purchased 775 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the purchase, the director directly owned 5,802 shares of the company’s stock, valued at approximately $205,332.78. The trade was a 15.42% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 4,871 shares of company stock worth $172,385 over the last quarter.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.